Showing 1 - 6 results of 6 for search 'Stanley B. Cohen', query time: 0.03s Refine Results
  1. 1
    Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

    Correction: Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis by Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch

    Published 2023-12-01
    Get full text
    Article
  2. 2
    Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis

    Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis by Gerd R. Burmester, Laura C. Coates, Stanley B. Cohen, Yoshiya Tanaka, Ivana Vranic, Edward Nagy, Irina Lazariciu, All-shine Chen, Kenneth Kwok, Lara Fallon, Cassandra Kinch

    Published 2023-07-01
    Get full text
    Article
  3. 3
    Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b/4 methotrexate withdrawal non-inferiority study (ORAL Shift)

    Efficacy and safety of tofacitinib modified-release 11 mg once daily plus methotrexate in adult patients with rheumatoid arthritis: 24-week open-label phase results from a phase 3b... by Boulos Haraoui, Janet Pope, Edward C Keystone, Eduardo Mysler, Tatjana Lukic, Harry Shi, Stanley B Cohen, Rebecca Germino, Lori Stockert, Annette Diehl, Sujatha Menon, Shixue Liu

    Published 2021-08-01
    Get full text
    Article
  4. 4
    Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

    Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme by Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt

    Published 2020-10-01
    Get full text
    Article
  5. 5
    Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

    Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis by Peter Nash, Atul Deodhar, Philip J Mease, Yoshiya Tanaka, Tim Shaw, Gerd R Burmester, Kevin L Winthrop, Alan D Irvine, Eduardo Mysler, Stanley B Cohen, Ana P Lacerda, John Liu, Hannah Palac, Emma Guttman‑Yassky

    Published 2023-02-01
    Get full text
    Article
  6. 6
    Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs

    Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs by Kevin L. Winthrop, Arne Yndestad, Dan Henrohn, Silvio Danese, Sara Marsal, Maria Galindo, John C. Woolcott, Hyejin Jo, Kenneth Kwok, Andrea B. Shapiro, Thomas V. Jones, Annette Diehl, Chinyu Su, Julian Panés, Stanley B. Cohen

    Published 2022-12-01
    Get full text
    Article

Search Tools: